Could fewer eye injections work for wet AMD? new study tests shorter loading phase
NCT ID NCT04932980
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests whether people with wet age-related macular degeneration (AMD) can safely extend the time between eye injections earlier than usual, skipping the standard three monthly loading doses. About 80 adults aged 50+ with active wet AMD will receive either aflibercept or brolucizumab and be followed for up to two years. The goal is to see if this approach reduces the number of injections needed while still controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Berner Augenklinik
Bern, 3007, Switzerland
Conditions
Explore the condition pages connected to this study.